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Results: 1466 patients from 149 centers in 24 countries were random-
ized to geﬁtinib (n=733) or docetaxel (n=733); 323 patients were of 
Asian racial origin. In the geﬁtinib and docetaxel treatment arms, 
respectively, 54% and 55% had adenocarcinoma, 36% and 33% were 
female, and 20% and 21% were never-smokers. 30%, 58%, 12% and 
25%, 63%, 12% had PS 0, 1, 2 in the geﬁtinib and docetaxel treatment 
arms, respectively and 15% and 17%, respectively, had undergone 2 
prior chemotherapy regimens. 453 patients provided a tumour sample 
giving at least one evaluable biomarker. Full results will be presented at 
the conference.
Conclusions: In this Phase III study comparing geﬁtinib with docetaxel 
in patients with locally advanced or metastatic NSCLC pretreated with 
platinum-based chemotherapy, the treatment groups were well balanced 
in terms of patient demographics and baseline characteristics. Full 
results will be presented at the conference.
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Background: Platinum-based chemotherapy is the standard of care for 
ﬁrst-line treatment of locally advanced and metastatic NSCLC. Gem-
citabine-cisplatin (GC) is a widely used doublet in this setting. In phase 
II studies, efﬁcacy results of pemetrexed-platinum doublets compare 
favorably with other active platinum-doublets. The combination of 
pemetrexed plus cisplatin (PC) has the potential to have similar efﬁcacy 
with more tolerability and more convenient administration. 
Methods: Patients with previously untreated stage IIIB or IV NSCLC 
and an ECOG PS of 0-1 were randomized to receive PC (P 500 mg/m2 
d1; C 75 mg/m2 d1) or GC (G 1250 mg/m2 d1,8; C 75 mg/m2 d1), every 
three weeks, up to 6 cycles. Both arms received folic acid, vitamin B12 
and dexamethasone. Randomization factors included stage, PS, gender, 
and history of brain metastases. The primary endpoint of this non-infe-
riority study was overall survival. Using the Cox proportional hazards 
model and a two-tailed 95% CI for the hazard ratio (HR), rejection of 
H0 occurs when the upper-bound of the HR CI is <1.17647, with an 
80% probability of rejecting H0 based on 1190 events. 
Results: From July 2004 to December 2005, 1725 patients were ran-
domized from 177 sites in 26 countries to PC (n=862) or GC (n=863). 
Both known prognostic factors and patient and disease characteristics 
were well-balanced between arms: median age 61 years, 70% male, 
64% PS 1, 76% stage IV NSCLC, 78% Caucasian, and 15% never 
smokers. Overall survival for patients randomized to PC was non-in-
ferior to GC (10.3 vs 10.3 mo [HR 0.94, 95%CI 0.84-1.05]), with the 
95% CI for HR included in the 1.176 non-inferiority margin. Progres-
sion free survival and response rates showed similarly robust non-
inferiority for PC vs GC (4.8 vs 5.1 mo [HR 1.04, 95%CI 0.94-1.15] 
and 31% vs 28%). Survival rates at 12 and 24 months were 43.5% 
vs 41.9% and 18.9% vs 14.0%, respectively. Hematologic grade 3/4 
drug-related toxicities were signiﬁcantly (p ≤ 0.001) lower for PC; 
neutropenia (15% vs 27%), anemia (6% vs 10%), and thrombocytope-
nia (4% vs 13%). Febrile neutropenia (grade 3/4, 1% vs 4%, p=0.002) 
and alopecia (12% vs 21%, p<0.001) were signiﬁcantly less for PC. 
Less grade 3/4 nausea (7% vs 4%, p=0.004) and anorexia (2% vs 1%, 
p=0.009) were observed for GC. In a pre-speciﬁed analysis of survival 
by histologic groups, PC had signiﬁcantly better survival than GC in 
adenocarcinoma (n=847, 12.6 vs 10.9 mo [HR 0.84, CI 0.71-0.98]) and 
in large cell histology (n=153, 10.4 vs 6.7 mo [HR 0.68, CI 0.48-0.97]). 
In contrast, there was a non signiﬁcant trend toward better survival with 
GC in squamous cell histology (n=473, 9.4 vs 10.8 mo [HR 1.22, CI 
0.99-1.50]). 
Conclusion: For ﬁrst-line treatment of advanced NSCLC, PC provides 
similar efﬁcacy with better tolerability and more convenient admin-
istration than GC. In addition, this is the ﬁrst NSCLC trial to report 
survival differences between platinum doublets according to histology, 
which may impact future treatment decisions.
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Background: Small cell lung cancer (SCLC) is a highly angiogenic tu-
mour. We hypothesized that thalidomide, an anti-angiogenic agent with 
tumour vasculature stabilizing, anti-cachexic and immuno-modulatory 
properties, when combined with chemotherapy and as maintenance 
treatment would improve survival in patients with poor prognosis 
SCLC. We previously demonstrated in a phase II study that low dose 
thalidomide when combined with chemotherapy and as maintenance 
agent was well tolerated without signiﬁcant toxicity (Lee, ASCO 
2002). Moreover, a randomized trial of 92 patients with extended-dis-
ease SCLC, who responded to chemotherapy, demonstrated a 3 month 
increase in survival in patients receiving thalidomide compared to 
placebo (Pujol ASCO 2006). Here, we present the preliminary results 
of a large randomised phase III trial of thalidomide in SCLC. 
Methods: Chemo-naive patients were entered into a double-blind 
placebo-controlled trial. Eligibility criteria included histologically or 
cytologically conﬁrmed SCLC, extensive or limited disease, age over 
18 years, ECOG performance status 0-3 and life expectancy of greater 
than 8 weeks. They were enrolled from 79 UK centres. All patients 
received up to 6 courses, every 3 weeks of Etoposide (120 mg/m2 IV on 
days 1 & 2, and 100mg bd given orally on day 3 or, given on day 2, in-
stead of IV, if required) and Carboplatin (AUC 5 or 6 given on day 1). 
Patients were randomized to receive placebo or thalidomide capsules, 
taken orally from starting chemotherapy, daily, for up to 2 years. The 
dose began at 100mg/day at the start of chemotherapy. If the patient 
was able to tolerate this dose, it was increased to 150mg/day at the end 
of chemotherapy for one month, then to 200mg/day for the rest of the 
trial. Thoracic radiotherapy and prophylactic cranial irradiation were 
offered to patients with initially limited disease who had a complete 
or partial response. Strict guidelines were given regarding contrace-
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tion and pregnancy testing. The end-points were overall survival, time 
to disease progression, response rates, toxicity and quality of life. The 
trial had 80% power to show a difference in the overall survival rate at 
2 years of 7% (from 12 to 19%).
Results: Between 2003 and 2006, 724 patients were randomized 
(placebo n=359; thalidomide n=365). The median age was 64 yrs 
(range 37-86); 43% were female; 49% had extensive disease; 73% had 
ECOG 0/1 and 27% had 2/3. Baseline patient characteristics were well 
balanced between the arms. The proportion of patients completing all 
6 intended chemotherapy cycles was 63% (placebo) and 60% (thalido-
mide), and the proportions of patients who had their chemotherapy 
dose delayed or reduced were similar between the trial arms. At the 
time of this analysis the median follow-up in all patients was 24 months 
and 611 had died (300 placebo and 311 thalidomide), of which 88% 
were reported to have died from lung cancer. There was no evidence 
of a difference in overall survival. The 2-year survival rate was 13% in 
both the placebo and thalidomide arms. The median survival was 10.5 
months (placebo) and 10.2 months (thalidomide). The hazard ratio was 
1.10 (95% CI 0.94 to 1.29), p=0.24 from a logrank test. The results 
on progression-free survival were consistent with those on overall 
survival, and again showed no beneﬁcial effect of using thalidomide. 
Subgroup analyses based on gender, age, performance status, tumour 
stage and alkaline phosphatase did not provide any evidence of a 
beneﬁcial effect of thalidomide for each factor. The main adverse ef-
fect associated with thalidomide was a thrombotic event. 103 patients 
experienced at least one such event (mainly pulmonary embolus and 
deep vein thrombosis) with 18% in the thalidomide arm compared to 
11% on placebo - relative risk of 1.68 (95% CI 1.16 to 2.44). There 
was no statistically signiﬁcant difference in haematological toxicities, 
36% (placebo) vs 37% (thalidomide), or non-haematological toxicities 
(excluding thrombotic events), 17% (placebo) vs 19% (thalidomide). 
Conclusions: In the largest phase III clinical trial ever conducted for 
patients with SCLC, thalidomide in combination with carboplatin and 
etoposide and as maintenance treatment did not improve survival and 
progression-free survival over carboplatin and etoposide alone and 
was associated with increased thrombotic events. The ﬁnal analyses, 
including those on quality of life and response rates, will be presented 
for both treatment groups.
